Suzhou-based Accro Bioscience (Suzhou) Limited (Accropeutics) has announced that it has received approval from the Australian Human Research Ethics Committee (HREC) to initiate a Phase I trial for its TYK2/JAK1 inhibitor pipeline candidate, AC-201. The study, which is randomized, double-blind, placebo-controlled, and involves single and multiple ascending doses, aims to evaluate the safety, tolerability, pharmacokinetics, and food effects of AC-201 in healthy adult volunteers.
AC-201: A Promising Inhibitor of TYK2/JAK1
AC-201, developed in-house, is Accropeutics’ third pipeline drug to reach the clinical stage. It is an innovative small-molecule inhibitor of TYK2/JAK1, known for its high activity, selectivity, and safety window. Preclinical testing has demonstrated the molecule’s potential in animal models for diseases such as psoriasis, as well as other inflammatory and autoimmune conditions.
Potential Impact of AC-201 on Psoriasis Treatment
As an oral drug candidate, AC-201 may offer convenience and efficacy benefits over current therapies for psoriasis. The initiation of the Phase I trial marks a significant step towards potentially transforming treatment options for patients suffering from this chronic skin condition.-Fineline Info & Tech
